Last update 01 Nov 2024

Chengdu Kangnuoxing Biopharma,Inc.

Private Company|
2017|
Sichuan Sheng, China
|
keymedbio.com

Overview

Tags

Otorhinolaryngologic Diseases
Congenital Disorders
Immune System Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Monoclonal antibody1
Top 5 TargetCount
IL-4Rα(Interleukin-4 receptor subunit alpha)1

Related

1
Drugs associated with Chengdu Kangnuoxing Biopharma,Inc.
Stapokibart
Target
IL-4Rα
Mechanism
IL-4Rα inhibitors
Active Org.
Chengdu Kangnuoxing Biopharma,Inc. [+4]
Originator Org.
Keymed Biomedical Technology (Chengdu) Co., Ltd.
Active Indication
Dermatitis, Atopic [+10]
Inactive Indication
Alzheimer Disease [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date10 Sep 2024
1
Clinical Trials associated with Chengdu Kangnuoxing Biopharma,Inc.
CTR20241776 / RecruitingPhase 3
一项评价司普奇拜单抗注射液用于结节性痒疹受试者的有效性和安全性的随机、双盲、安慰剂对照III期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of sepakinumab injection in subjects with nodular prurigo
100 Clinical Results associated with Chengdu Kangnuoxing Biopharma,Inc.
Login to view more data
0 Patents (Medical) associated with Chengdu Kangnuoxing Biopharma,Inc.
Login to view more data
100 Deals associated with Chengdu Kangnuoxing Biopharma,Inc.
Login to view more data
100 Translational Medicine associated with Chengdu Kangnuoxing Biopharma,Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Stapokibart
 ( IL-4Rα )		Dermatitis, Atopic
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free